Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%
Notice Regarding Repurchase of Own Shares
Notice Regarding Repurchase of Own Shares
Partial Correction to “First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials ”
Notice Regarding Repurchase of Own Shares
Partial Correction to “First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials ”
First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials
Notice Regarding Absorption-type Merger (Simplified and Short-Form Merger) of a Wholly Owned Subsidiary
Notice Regarding Stock Split and Partial Amendment to the Articles of Incorporation in Conjunction with the Stock Split
Notice Regarding Repurchase and Cancellation of Own Shares
Summary of Consolidated Financial Results for the Six Months Ended November 30, 2024(Under Japanese GAAP)
Daito Pharma, First Half Ordinary Profit Decreases by 36%, Sep-Nov Ordinary Profit Decreases by 60%
Daito Pharmaceutical Co.,Ltd., June-August (1Q) Ordinary Profit Decreases by 10%